Literature DB >> 25987610

Retrograde Trafficking Inhibitor of Shiga Toxins Reduces Morbidity and Mortality of Mice Infected with Enterohemorrhagic Escherichia coli.

T Secher1, A Shima1, K Hinsinger2, J C Cintrat2, L Johannes3, J Barbier4, D Gillet4, E Oswald5.   

Abstract

The most deadly outbreak of Escherichia coli O104:H4 occurred in Europe in 2011. Here, we evaluated the effects of the retrograde trafficking inhibitor Retro-2(cycl) in a murine model of E. coli O104:H4 infection. Systemic treatment with Retro-2(cycl) significantly reduced body weight loss and improved clinical scores and survival rates for O104:H4-infected mice. The present data established that Retro-2(cycl) contributes to the protection of mice against O104:H4 infection and may represent a novel approach to limit Shiga toxin-producing Escherichia coli (STEC)-induced toxicity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25987610      PMCID： PMC4505253          DOI： 10.1128/AAC.00455-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Inhibition of retrograde transport protects mice from lethal ricin challenge.

Authors:  Bahne Stechmann; Siau-Kun Bai; Emilie Gobbo; Roman Lopez; Goulven Merer; Suzy Pinchard; Laetitia Panigai; Danièle Tenza; Graça Raposo; Bruno Beaumelle; Didier Sauvaire; Daniel Gillet; Ludger Johannes; Julien Barbier
Journal:  Cell       Date:  2010-04-16       Impact factor: 41.582

Review 2.  Delivery into cells: lessons learned from plant and bacterial toxins.

Authors:  K Sandvig; B van Deurs
Journal:  Gene Ther       Date:  2005-06       Impact factor: 5.250

Review 3.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

4.  Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release.

Authors:  M N Neely; D I Friedman
Journal:  Mol Microbiol       Date:  1998-06       Impact factor: 3.501

5.  Different classes of antibiotics differentially influence shiga toxin production.

Authors:  Colleen Marie McGannon; Cynthia Ann Fuller; Alison Ann Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 6.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 7.  Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials.

Authors:  Mini Michael; Elizabeth J Elliott; Jonathan C Craig; Greta Ridley; Elisabeth M Hodson
Journal:  Am J Kidney Dis       Date:  2008-10-31       Impact factor: 8.860

8.  Development of a lethal Shiga toxin-producing Escherichia coli-infection mouse model using multiple mitomycin C treatment.

Authors:  Kensuke Shimizu; Takashi Asahara; Koji Nomoto; Ryuichiro Tanaka; Takashi Hamabata; Ayako Ozawa; Yoshifumi Takeda
Journal:  Microb Pathog       Date:  2003-07       Impact factor: 3.738

9.  Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial.

Authors:  Howard Trachtman; Avital Cnaan; Erica Christen; Kathleen Gibbs; Sanyi Zhao; David W K Acheson; Robert Weiss; Frederick J Kaskel; Adrian Spitzer; Gladys H Hirschman
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

10.  Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli.

Authors:  Eduardo L López; Maria M Contrini; Eduardo Glatstein; Silvia González Ayala; Roberto Santoro; Daniel Allende; Gustavo Ezcurra; Eduardo Teplitz; Tamotsu Koyama; Yoichi Matsumoto; Hiroaki Sato; Kazuaki Sakai; Satoru Hoshide; Keiji Komoriya; Takuya Morita; Ronald Harning; Sheldon Brookman
Journal:  Antimicrob Agents Chemother       Date:  2009-10-12       Impact factor: 5.191
View more
  14 in total

1.  Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions.

Authors:  Gilad Sivan; Andrea S Weisberg; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

2.  C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virus.

Authors:  Yu Wu; Nassim Mahtal; Eléa Paillares; Léa Swistak; Sara Sagadiev; Mridu Acharya; Caroline Demeret; Sylvie Van Der Werf; Florence Guivel-Benhassine; Olivier Schwartz; Serena Petracchini; Amel Mettouchi; Lucie Caramelle; Pierre Couvineau; Robert Thai; Peggy Barbe; Mathilde Keck; Priscille Brodin; Arnaud Machelart; Valentin Sencio; François Trottein; Martin Sachse; Gaëtan Chicanne; Bernard Payrastre; Florian Ville; Victor Kreis; Michel-Robert Popoff; Ludger Johannes; Jean-Christophe Cintrat; Julien Barbier; Daniel Gillet; Emmanuel Lemichez
Journal:  iScience       Date:  2022-06-06

3.  Vaccinia Virus Uses Retromer-Independent Cellular Retrograde Transport Pathways To Facilitate the Wrapping of Intracellular Mature Virions during Virus Morphogenesis.

Authors:  Kate Harrison; Ismar R Haga; Tali Pechenick Jowers; Seema Jasim; Jean-Christophe Cintrat; Daniel Gillet; Thomas Schmitt-John; Paul Digard; Philippa M Beard
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  Baicalin Protects Mice from Lethal Infection by Enterohemorrhagic Escherichia coli.

Authors:  Yong Zhang; Zhimin Qi; Yan Liu; Wenqi He; Cheng Yang; Quan Wang; Jing Dong; Xuming Deng
Journal:  Front Microbiol       Date:  2017-03-09       Impact factor: 5.640

Review 5.  Protection against Shiga Toxins.

Authors:  Simona Kavaliauskiene; Anne Berit Dyve Lingelem; Tore Skotland; Kirsten Sandvig
Journal:  Toxins (Basel)       Date:  2017-02-03       Impact factor: 4.546

Review 6.  Shiga Toxin Therapeutics: Beyond Neutralization.

Authors:  Gregory Hall; Shinichiro Kurosawa; Deborah J Stearns-Kurosawa
Journal:  Toxins (Basel)       Date:  2017-09-19       Impact factor: 4.546

Review 7.  Targeting the Early Endosome-to-Golgi Transport of Shiga Toxins as a Therapeutic Strategy.

Authors:  Danyang Li; Andrey Selyunin; Somshuvra Mukhopadhyay
Journal:  Toxins (Basel)       Date:  2020-05-22       Impact factor: 4.546

Review 8.  The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery-The GL-Lect Hypothesis.

Authors:  Ludger Johannes
Journal:  Molecules       Date:  2021-05-31       Impact factor: 4.411

Review 9.  Shiga Toxin-A Model for Glycolipid-Dependent and Lectin-Driven Endocytosis.

Authors:  Ludger Johannes
Journal:  Toxins (Basel)       Date:  2017-10-25       Impact factor: 4.546

10.  Functional dissection of the retrograde Shiga toxin trafficking inhibitor Retro-2.

Authors:  Alison Forrester; Stefan J Rathjen; Maria Daniela Garcia-Castillo; Collin Bachert; Audrey Couhert; Livia Tepshi; Sylvain Pichard; Jennifer Martinez; Mathilde Munier; Raphael Sierocki; Henri-François Renard; César Augusto Valades-Cruz; Florent Dingli; Damarys Loew; Christophe Lamaze; Jean-Christophe Cintrat; Adam D Linstedt; Daniel Gillet; Julien Barbier; Ludger Johannes
Journal:  Nat Chem Biol       Date:  2020-02-17       Impact factor: 15.040
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.